Science
Mechanism of Action
This extract modulates the skin's inflammatory response by suppressing Th2 cytokines, such as IL-4, and inhibiting Nerve Growth Factor (NGF)-induced dendritic cell extension to effectively reduce pruritus (itching). Its high concentration of Koji Polysaccharides (IBF) accelerates structural barrier recovery and balances the skin microbiome, while simultaneous tyrosinase inhibition provides a secondary benefit of tone evening.
Research
Clinical Evidence
High confidence0.2%
Key findings
- 01 Clinical application of a 0.2% Koji Polysaccharide fraction resulted in significant objective and subjective improvement in atopic dermatitis symptoms and inflammatory markers over a 30-day period.
- 02 In vitro testing demonstrated a measurable inhibition of adipocyte differentiation and lipid accumulation, suggesting potential applications in lipid regulation and body contouring.
Transparency
Dusting Analysis
With clinical efficacy established at a low threshold of 0.2%, this ingredient is frequently included at 'label-only' concentrations (below 0.1%) in mass-market formulations to claim fermented-soy benefits without delivering the therapeutic anti-atopic response.
The Formula
Formulation
Stability
Highly heat-sensitive; bioactive polysaccharides degrade if exposed to temperatures above 40°C during manufacture. Must be incorporated during the cool-down phase.
Synergies
- Ceramides
- Niacinamide
- Hyaluronic Acid
Conflicts
- High temperatures (>50°C)
- Strongly alkaline formulations
- Strongly acidic peels
Safety
Safety Profile
While the specific INCI is not yet reviewed by CIR, the constituent Aspergillus ferments and soy derivatives are well-documented for safety in both topical and food-grade applications.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A high-performance biological active that offers clinically validated relief for atopic and compromised skin at concentrations as low as 0.2%.
Related
Similar Ingredients
Finding similar ingredients…